Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accounts Payables (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Accounts Payables for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 70.99% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 70.99% year-over-year, with the annual reading at $1.2 million for FY2025, 70.99% down from the prior year.
  • Accounts Payables for Q4 2025 was $1.2 million at TScan Therapeutics, down from $6.4 million in the prior quarter.
  • The five-year high for Accounts Payables was $6.4 million in Q3 2025, with the low at $1.2 million in Q4 2025.
  • Average Accounts Payables over 5 years is $3.4 million, with a median of $3.1 million recorded in 2024.
  • Peak annual rise in Accounts Payables hit 133.91% in 2025, while the deepest fall reached 70.99% in 2025.
  • Over 5 years, Accounts Payables stood at $1.8 million in 2021, then surged by 64.99% to $2.9 million in 2022, then fell by 18.48% to $2.4 million in 2023, then skyrocketed by 80.2% to $4.3 million in 2024, then plummeted by 70.99% to $1.2 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.2 million, $6.4 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.